The dutch FOm/f approach to gender balance in physics

Almost 20 years ago, the Dutch Foundation for Fundamental Research on Matter (FOM) launched the FOm/f programme to encourage women to continue a career in physics after finishing their PhDs. As of 2016, 86% of the FOm/f laureates hold permanent positions in academic research, while 11 laureates have become full-time physics professors. Key to the success of the FOm/f programme is a customised personal approach. Since September 2015, FOM has been a partner in the European Horizon 2020 GENERA project, which aims to implement Gender Equality Plans customized for physics. The positive experience with the personal approach of the FOm/f programme and dedicated tenure-track programmes for women will be paramount for a future Gender Equality Plan for improving the gender balance in the physics community.</p

GENERA gender in physics days in Europe

The GENERA European Horizon 2020 project aims at designing and implementing gender equality plans customised for physics. The three-year project started in September 2015. GENERA's activities include the national Gender in Physics Day in each European country participating in the GENERA project. Typically, at these days, national physics managers, human resources managers, and gender equality policy officers meet with senior and early-career physicists to review the status quo and formulate recommendations for improving the gender balance in the national physics community. We will report on the recommendations of the first GENERA Gender in Physics Day organised in 2016 in the Netherlands.</p

Women in physics in the Netherlands:Recent Developments

Although women are still a small minority in physics in the Netherlands, their visibility has increased markedly over the past five years. The measures put in place after the first IUPAP Women in Physics Conference in 2002 have in fact not increased the total number of female staff, but put the spotlight on female talent in physics. Affirmative actions by Dutch science faculties and physics departments have brought about a more than fivefold increase of female full professors: by now only one university is left without a female chair. At the assistant and associate professor levels, the MEERVOUD and ASPASIA programs of NWO (the national funding agency for scientific research) have been a success. The FOm/f program of the Foundation for Fundamental Research on Matter has accomplished its goal of stimulating the participation of women in physics through covering salary costs, giving research funding and postdoctoral positions, and highlighting outstanding female physicists through the MINERVA prize. Despite these success stories, the number of female physics students is still far too low, and even if there is an important influx of foreigners at all career levels from the PhD student upward, reaching 10% women in permanent positions in physics is still a goal for the future

A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma : evaluation of safety and clinical and immunologic response

Background: Current first-line standard of therapy for metastatic urothelial carcinoma is platinum-based combination chemotherapy. Pembrolizumab in phase III has demonstrated a promising overall response rate of 21.1% in patients with progression or recurrence after platinum-based chemotherapy. Preclinical and clinical evidence suggests that radiotherapy has a systemic anti-cancer immune effect and can increase the level of PD-L1 and tumor infiltrating lymphocytes in the tumor microenvironment. These findings gave rise to the hypothesis that the combination of radiotherapy with anti-PD1 treatment could lead to a synergistic effect, hereby enhancing response rates. Methods: The phase I part will assess the dose limiting toxicity of the combination treatment of stereotactic body radiotherapy (SBRT) with four cycles of pembrolizumab (200 mg intravenously, every 3 weeks) in patients with metastatic urothelial carcinoma. The dose of both pembrolizumab and SBRT will be fixed, yet the patients will be randomized to receive SBRT either before the first cycle of pembrolizumab or before the third cycle of pembrolizumab. SBRT will be delivered (24 Gy in 3 fractions every other day) to the largest metastatic lesion. Secondary objectives include response rate according to RECIST v1.1 and immune related response criteria, progression-free survival and overall survival. The systemic immune effect triggered by the combination therapy will be monitored on various time points during the trial. The PD-L1/TIL status of the tumors will be analyzed via immunohistochemistry and response rates in the subgroups will be analyzed separately. A Simon's two-stage optimum design is used to select the treatment arm associated with the best response rate and with acceptable toxicity to proceed to the phase II trial. In this phase, 13 additional patients will be accrued to receive study treatment. Discussion: The progress made in the field of immunotherapy has lead to promising breakthroughs in various solid malignancies. Unfortunately, the majority of patients do not respond. The current trial will shed light on the toxicity and potential anti-tumor activity of the combination of radiotherapy with anti-PD1 treatment and may identify potential new markers for response and resistance to therapy

Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood

Introduction Late cardiotoxicity is a known complication of anthracycline therapy but the long-term effects of low cumulative doses are not well documented. We studied late cardiotoxicity in survivors of childhood acute lymphoblastic leukemia (ALL) treated with low anthracycline doses 10 to 20 years earlier. Methods Seventy-seven ALL survivors who received a cumulative anthracycline dose <250 mg/m(2) and were at least 10 years after treatment were evaluated for signs of clinical heart failure. Cardiac function was assessed by echocardiography including tissue Doppler measurements of the septal mitral annulus in 37 ALL survivors 10.6-18.3 years (median 13.3 years) after anthracycline treatment with cumulative doses of 180 (n=19) or 240 mg/m(2) (n=18). The control group consisted of 30 healthy volunteers matched for age, sex, BSA, and BMI. Results No clinical relevant cardiotoxicity was found. Left ventricular shortening fraction (SF) was significantly reduced in male ALL survivors. Three of the 19 male ALL survivors had an SF below 30%. Male ALL survivors showed a significantly lower early filling velocity to atrial contraction velocity ratio but myocardial velocity during early filling was comparable between patients and controls. ALL survivors had a significantly longer isovolumetric relaxation time (IVRT). Thirty percent of the ALL survivors have an abnormal IVRT compared to the normal range of the controls. Conclusion and implications for cancer survivors At a median of 13.3 years after exposure to cumulative doses of anthracyclines of 180 or 240 mg/m(2), no clinical relevant cardiotoxicity was found but subclinical cardiac abnormalities were present in 30% of the patients

Cross-Border Dissemination of Methicillin-Resistant Staphylococcus aureus, Euregio Meuse-Rhin Region

MRSA clones were associated with hospital-associated clonal complexes and with Panton-Valentine leukocidin–positive community-associated MRSA

Writing in Britain and Ireland, c. 400 to c. 800

No abstract available

Event reconstruction for KM3NeT/ORCA using convolutional neural networks

The KM3NeT research infrastructure is currently under construction at two locations in the Mediterranean Sea. The KM3NeT/ORCA water-Cherenkov neutrino detector off the French coast will instrument several megatons of seawater with photosensors. Its main objective is the determination of the neutrino mass ordering. This work aims at demonstrating the general applicability of deep convolutional neural networks to neutrino telescopes, using simulated datasets for the KM3NeT/ORCA detector as an example. To this end, the networks are employed to achieve reconstruction and classification tasks that constitute an alternative to the analysis pipeline presented for KM3NeT/ORCA in the KM3NeT Letter of Intent. They are used to infer event reconstruction estimates for the energy, the direction, and the interaction point of incident neutrinos. The spatial distribution of Cherenkov light generated by charged particles induced in neutrino interactions is classified as shower- or track-like, and the main background processes associated with the detection of atmospheric neutrinos are recognized. Performance comparisons to machine-learning classification and maximum-likelihood reconstruction algorithms previously developed for KM3NeT/ORCA are provided. It is shown that this application of deep convolutional neural networks to simulated datasets for a large-volume neutrino telescope yields competitive reconstruction results and performance improvements with respect to classical approaches